The landscape of oncology is shifting from broad-spectrum treatments toward "biological missiles" that target cancer with surgical precision. At the heart of this transformation is the Antibody Drug Conjugate Market. By combining the targeting capabilities of monoclonal antibodies with the cell-killing power of cytotoxic drugs, ADCs are redefining survival rates for patients worldwide. The...